Home > Cardiology > IV aspirin, heparin during endovascular stroke treatment tied to increased intracranial bleeding risk

IV aspirin, heparin during endovascular stroke treatment tied to increased intracranial bleeding risk


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
The Lancet
Reuters Health - 16/03/2022 - Periprocedural intravenous (IV) aspirin and/or unfractionated heparin during endovascular stroke treatment are both associated with an increased risk of intracranial hemorrhage with no evidence of benefit, researchers say.  "We were surprised by the results, as our hypothesis - based on previous observational studies - was that treatment with periprocedural antithrombotics would be beneficial," Dr. Wouter van der Steen of Erasmus University Medical Center in Rotterdam told Reuters Health by email. "We can now recommend avoiding the evaluated dosages of aspirin and heparin during endovascular stroke treatment. We consider it wise to implement this in the guidelines."


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on